Although the role of GRAMD1A in tumorigenesis has been largely unexplored in other cancer types, our study is the first to demonstrate that elevated GRAMD1A expression is linked to poor overall survival (OS) and progression-free survival (PFS) in Wilms tumor (WT) patients. This evidence concerns the gene GRAMD1A and Wilms tumor.